Elicio Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 13, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Operating expenses: | ||||
| Research and development | $7,208 | $7,264 | $22,947 | $17,692 |
| General and administrative | 3,136 | 3,507 | 8,563 | 8,661 |
| Total operating expenses | 10,344 | 10,771 | 31,510 | 26,353 |
| Loss from operations | (10,344) | (10,771) | (31,510) | (26,353) |
| Other (expense) income | ||||
| Change in fair value of warrant liabilities | (5,617) | 6 | (3,279) | (17) |
| Loss on issuance of pre-funded warrants | (2,924) | — | (3,502) | — |
| Change in fair value of derivative liability | — | — | — | 429 |
| Gain on extinguishment of promissory notes payable | — | — | — | 604 |
| Gain (loss) on sale of equipment | — | (105) | 3 | (105) |
| Foreign exchange transaction (loss) gain | (1) | (33) | 143 | (45) |
| Interest income | 185 | 246 | 472 | 298 |
| Interest expense | (137) | (1) | (221) | (1,057) |
| Total other (expense) income, net | (8,494) | 113 | (6,384) | 107 |
| Net loss | (18,838) | (10,658) | (37,894) | (26,246) |
| Other comprehensive gain (loss): | ||||
| Foreign currency translation adjustment | 36 | (23) | (5) | (25) |
| Comprehensive loss | $(18,802) | $(10,681) | $(37,899) | $(26,271) |
| Net loss per common share, basic and diluted (1) | $(1.39) | $(1.27) | $(3.23) | $(6.75) |
| Weighted average common shares and pre-funded warrants outstanding, basic and diluted (1) | 13,582,345 | 8,376,384 | 11,720,527 | 3,894,073 |
(1)As described in Note 2 to these Condensed Consolidated Financial Statements, the Company has revised the net loss per share of common stock and weighted average shares of common stock outstanding for the nine month period ended 2023.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.